Gino In

Associate Professor of Clinical Medicine

Image of Gino In
Is this your profile? Click to edit

Overview

Gino K. In, MD, MPH, is a medical oncologist who specializes in solid tumor and cutaneous oncology. He completed his fellowship training in hematology and oncology at the University of Southern California, Keck School of Medicine, where he was the chief medical oncology fellow. He subsequently joined the USC Norris Comprehensive Cancer Center, and now serves as Assistant Professor of Clinical Medicine in the Division of Oncology, and Assistant Professor of Dermatology. Dr. In’s research focus includes the multi-disciplinary management of melanoma and other skin cancers, including cutaneous squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma. He has a specific interest in non-UV related melanoma subtypes and intratumoral therapies. Dr. In is the lead primary investigator for cutaneous oncology clinical trials at USC, including studies through the National Cancer Institute, California Cancer Consortium, and Southwest Oncology Group.

Awards

  • University of Southern California: Chief Medical Oncology Fellow

Education and Training

  • University of Southern California, Los Angeles, CA — Fellowship — 2016 — Hematology/Oncology
  • SUNY Downstate Medical Center, Brooklyn, NY — Residency — 2011 — Internal Medicine
  • SUNY Downstate Medical Center, Brooklyn, NY — Internship — 2010
  • Ross University, North Brunswick Township, NJ — MD — 2010 — Medicine
  • Emory University, Atlanta, GA — MPH — 2006 — Environmental/Occupational Health
  • Emory University, Atlanta, GA — BS — 2002

Research Keywords

  • Medical Oncology
  • Skin Cancer
  • Melanoma
  • Acral Lentiginous Melanoma
  • Uveal Melanoma
  • Mucosal Melanoma
  • Squamous Cell Carcinoma
  • Basal Cell Carcinoma
  • Merkel Cell Carcinoma
  • Dermatofibrosarcoma Protuberans
  • Porocarcinoma

Publications

  • Ancestry and somatic profile predict acral melanoma origin and prognosis. medRxiv. 2025 Aug 08.. View in PubMed
  • Chemoimmunotherapy in Advanced, PD-1 Refractory Cutaneous Squamous Cell Carcinoma: Insights From Two Immunocompromised Patient Cases. Case Rep Oncol Med. 2025; 2025:4443916.. View in PubMed
  • A case of cutaneous angiosarcoma with intradermal metastases responding to PD-1 inhibition-based immunotherapy. JAAD Case Rep. 2025 Oct; 64:67-70.. View in PubMed
  • RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE). J Clin Oncol. 2025 11 20; 43(33):3589-3599.. View in PubMed
  • Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301). J Clin Oncol. 2025 Aug 10; 43(23):2658.. View in PubMed
  • Are guidelines guiding? A mixed methods study examining the integration of ASCO fertility discussion guidelines in practice among oncologists and adolescents and young adults at an NCI-designated Comprehensive Cancer Center. J Cancer Surviv. 2025 Jun 19.. View in PubMed
  • Comprehensive Profiling of Acral Lentiginous Melanoma Reveals Downregulated Immune Activation Compared to Cutaneous Melanoma. Pigment Cell Melanoma Res. 2025 05; 38(3):e70027.. View in PubMed
  • Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301). J Clin Oncol. 2025 05 20; 43(15):1800-1809.. View in PubMed
  • Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma. Br J Dermatol. 2025 01 24; 192(2):316-326.. View in PubMed
  • Acral lentiginous melanoma. Part I. Epidemiology, etiology, clinical presentation, and diagnosis. J Am Acad Dermatol. 2026 02; 94(2):421-432.. View in PubMed